Solute carrier family 22 member 1 (SLC22A1) (SLC22A1)

Solute carrier family 22 member 1 (SLC22A1), also known as Organic Cation Transporter 1 (OCT1), is a critical membrane transporter primarily expressed on the basolateral membrane of hepatocytes in the liver [1, 3, 12]. It functions as a uniporter that facilitates the uptake of a wide range of endogenous organic cations, including neurotransmitters like dopamine and essential nutrients like thiamine [1, 2, 8]. Beyond its physiological roles, SLC22A1 is a major determinant of the disposition of numerous therapeutic drugs, such as the first-line antidiabetic agent metformin and the tyrosine kinase inhibitor imatinib [7, 13, 16]. The transporter is involved in various disease processes, including metabolic disorders like type 2 diabetes and cancers such as hepatocellular carcinoma and chronic myeloid leukemia [4, 5, 9]. Genetic polymorphisms in the SLC22A1 gene serve as vital biomarkers for predicting individual drug responses and the risk of adverse effects, such as metformin-induced gastrointestinal distress [6, 7, 14]. Furthermore, SLC22A1 is a frequent site of drug-drug interactions, where its inhibition by co-administered drugs can lead to significant changes in the pharmacokinetics of its substrates [4, 7, 11]. Understanding the functional status of SLC22A1 is therefore essential for optimizing drug therapy and ensuring patient safety in clinical practice [10, 14].

Other names

Organic cation transporter 1OCT1hOCT1HOCT1Oct1_cds

SLC22A1 facilitates the sodium-independent transport of organic cations across the plasma membrane via facilitated diffusion [1, 3]. It is primarily responsible for the hepatic uptake of cationic drugs from the portal blood into hepatocytes, which is a prerequisite for their subsequent metabolism or biliary excretion [4, 7, 12].